$Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis$

Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis

Abstract: Clarithromycin is a macrolide antibiotic with anti–multiple myeloma (MM) activity when combined with dexamethasone and immunomodulatory agents. This phase 1/2 study of clarithromycin, ixazomib, pomalidomide, and dexamethasone (ClIPd) assessed tolerability and efficacy in relapsed/refractor...

Full description

Saved in:

Bibliographic Details
Main Authors:	Aaron S. Rosenberg, Emanual Maverakis, Caitlin Costello, Elizabeth A. Brem, Matthew Joseph Wieduwilt, Guillaume Luxardi, Paul Kaesberg, Keon Abedi, Samantha Herbert, Joseph Tuscano
Format:	Article
Language:	English
Published:	Elsevier 2025-08-01
Series:	Blood Neoplasia
Online Access:	http://www.sciencedirect.com/science/article/pii/S2950328025000020
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
by: Andrew J. Yee, et al.
Published: (2025-03-01)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
by: Zhongjun Huo, et al.
Published: (2023-02-01)

Pomalidomide in Combination with Low-Dose Dexamethasone as the Treatment of “Double Refractory” Multiple Myeloma
by: AV Petrov, et al.
Published: (2017-07-01)

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma
by: Yan Wang, et al.
Published: (2025-02-01)

The role of pomalidomide in treatment of relapse and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2022-01-01)

Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01)

Pharmacoeconomic evaluation of carfilzomib versus ixazomib for the treatment of relapsed and refractory multiple myeloma
by: Lin Wang, et al.
Published: (2025-12-01)

A retrospective study of isatuximab-pomalidomide-dexamethasone in relapsed/refractory systemic AL amyloidosis
by: Sargam Rachit Vohra, et al.
Published: (2025-07-01)

Balancing the Risk of Cardiotoxicity Outcomes in Treatment Selection for Multiple Myeloma: A Retrospective Multicenter Evaluation of Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (KRd)
by: Benjamin J. Lee, et al.
Published: (2025-06-01)

The Use of Pomalidomide in the Treatment of Relapsed/Refractory Multiple Myeloma in Patients with Renal Failure
by: IG Rekhtina, et al.
Published: (2018-10-01)

Pomalidomide for the management of relapsed and refractory multiple myeloma: a case report and review of literature
by: S. V. Semochkin
Published: (2015-10-01)

Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
by: I. G. Rekhtina, et al.
Published: (2019-04-01)

Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data
by: Enrica Antonia Martino, et al.
Published: (2025-03-01)

PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA
by: M. Yu. Frolov, et al.
Published: (2017-08-01)

Isatuximab–dexamethasone–pomalidomide combination effects on serum M protein and PFS in myeloma: Development of a joint model using phase I/II data
by: Antoine Pitoy, et al.
Published: (2024-12-01)

BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma
by: Yuhan Yan, et al.
Published: (2024-11-01)

Effects of monoclonal antibody daratumumab combined with ixazomib-based treatment regimen on survival of patients with relapsed/refractory multiple myeloma
by: Peng Lang, et al.
Published: (2025-01-01)

Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)
by: Josip Batinić, et al.
Published: (2024-11-01)

Long-Term Effectiveness and Safety of Isatuximab in Combination with Pomalidomide and Dexamethasone in a Japanese Patient with Refractory Multiple Myeloma and 1q21 Amplification: A Case Report
by: Takanori Yoshioka, et al.
Published: (2025-01-01)

Comparison of health technology assessment for new medicines in France and England: an example based on ixazomib for patients with relapsed or refractory multiple myeloma
by: Xavier Armoiry, et al.
Published: (2019-01-01)

Ixazomib-associated skin exfoliation
by: Yali Zhang, et al.
Published: (2022-04-01)

Case report: pomalidomide as maintenance after salvage autologous stem cell transplantation in a patient with relapsed multiple myeloma
by: S. V. Semochkin, et al.
Published: (2023-12-01)

BRAIN-INVOLVED MULTIPLE MYELOMA: STABILITY ACHIEVED WITH BENDAMUSTINE-POMALIDOMIDE, RADIOTHERAPY AND DARATUMUMAB-BASED THERAPY
by: Bengisu Ece Duman, et al.
Published: (2024-12-01)

Treatment pattern among patients with relapsed/refractory multiple myeloma (RRMM) who had received pomalidomide-based regimens in Taiwan
by: Chieh-Lin Jerry Teng, et al.
Published: (2024-12-01)

Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma
by: James A. Davis, et al.
Published: (2025-03-01)

Drug-Induced Thrombotic Microangiopathy due to Cumulative Toxicity of Ixazomib
by: Suheil Albert Atallah-Yunes, et al.
Published: (2018-01-01)

Clarithromycin crystalluria
by: Zhao Weihua, et al.
Published: (2025-02-01)

Clarithromycin for Children
by: Susan M King
Published: (1995-01-01)

A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)
by: Chandramouli Nagarajan, et al.
Published: (2025-06-01)

Clinical Pharmacokinetics of Clarithromycin
by: Marc LeBel
Published: (1993-01-01)

Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report
by: Reilly Fankhauser, et al.
Published: (2024-11-01)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
by: Johan Lund, et al.
Published: (2018-06-01)

Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study
by: Juan M. Cano-Calderón, et al.
Published: (2025-01-01)

CLARITHROMYCIN IN TREATMENT OF TONSILLITIS IN CHILDREN
by: Yu. L. Soldatskii
Published: (2012-07-01)

Pathophysiology of Antibiotic Resistance: Clarithromycin
by: Diane E Taylor
Published: (2000-01-01)

Identification and removal of a cryptic impurity in pomalidomide-PEG based PROTAC
by: Bingnan Wang, et al.
Published: (2025-02-01)

Outcomes of Idecabtagene Vicleucel Therapy in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience
by: Aaron Trando, et al.
Published: (2024-12-01)

Mesenchymal Stem Cells Inhibit the Effects of Dexamethasone in Multiple Myeloma Cells
by: Mingyang Deng, et al.
Published: (2022-01-01)

Combined Proteasome and Autophagy Inhibition in Relapsed/Refractory Multiple Myeloma—A Phase I Trial of Hydroxychloroquine, Carfilzomib, and Dexamethasone
by: Tobias S. Slørdahl, et al.
Published: (2025-02-01)